News
LUNG
11.36
-5.18%
-0.62
Top 5 Health Care Stocks That You May Want To Dump In Q1 2023
Benzinga · 02/28 13:40
Benzinga's Top Ratings Upgrades, Downgrades For February 27, 2023
Benzinga · 02/27 15:00
Wells Fargo Upgrades Pulmonx to Overweight, Raises Price Target to $15
Benzinga · 02/27 11:52
Wells Fargo Upgrades Pulmonx to Overweight From Equalweight, Adjusts Price Target to $15 From $10
Wells Fargo Upgrades Pulmonx to Overweight From Equalweight, Adjusts Price Target to $15 From $10
MT Newswires · 02/27 09:35
Why Shares of Pulmonx Rose This Week
NASDAQ · 02/24 21:00
Where Pulmonx Stands With Analysts
Benzinga · 02/24 20:01
Citigroup Maintains Buy on Pulmonx, Raises Price Target to $12
Benzinga · 02/24 13:38
Why Domino's Pizza Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga · 02/23 17:59
Morgan Stanley Remains a Hold on Pulmonx (LUNG)
TipRanks · 02/23 16:26
Comfort Systems, Gannett, CommScope And Other Big Stocks Moving Higher On Thursday
Benzinga · 02/23 16:15
Ocean, NeoGenomics top healthcare gainers; Chemomab, American Well among losers
Seeking Alpha · 02/23 15:01
Nasdaq Jumps 100 Points; US GDP Rises 2.7% In Q4
Benzinga · 02/23 14:51
Canaccord Genuity Maintains Buy on Pulmonx, Raises Price Target to $20
Benzinga · 02/23 14:46
--Morgan Stanley Adjusts Price Target on Pulmonx to $11 From $9.50, Keeps Equalweight Rating
--Morgan Stanley Adjusts Price Target on Pulmonx to $11 From $9.50, Keeps Equalweight Rating
MT Newswires · 02/23 12:06
Canaccord Genuity Adjusts Price Target on Pulmonx to $20 From $18, Maintains Buy Rating
Canaccord Genuity Adjusts Price Target on Pulmonx to $20 From $18, Maintains Buy Rating
MT Newswires · 02/23 11:26
Pulmonx Q4 EPS $(0.38) Beats $(0.42) Estimate, Sales $15.43M Beat $13.98M Estimate
Benzinga · 02/22 21:38
-- Earnings Flash (LUNG) PULMONX CORPORATION Posts Q4 Revenue $15.4M, vs. Street Est of $14M
-- Earnings Flash (LUNG) PULMONX CORPORATION Posts Q4 Revenue $15.4M, vs. Street Est of $14M
MT Newswires · 02/22 16:20
Earnings Scheduled For February 22, 2023
Benzinga · 02/22 10:26
Point72 Asset Management adds Salesforce, Netflix, exits Palo Alto Networks
Seeking Alpha · 02/15 01:39
Pulmonx: Price Structure, Trend Studies Point To Further Congestion (Technical Analysis)
Seeking Alpha · 02/14 06:37
More
Webull provides a variety of real-time LUNG stock news. You can receive the latest news about Pulmonx Corp through multiple platforms. This information may help you make smarter investment decisions.
About LUNG
Pulmonx Corporation is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its solutions include Zephyr Endobronchial Valve (Zephyr Valve), the Chartis Pulmonary Assessment System (Chartis System) and the StratX Lung Analysis Platform (StratX Platform), which is designed to treat emphysema patients. The Zephyr Valve, Chartis System and StratX Platform, is designed to treat severe emphysema patients who, despite medical management, are still profoundly symptomatic and either do not want or are ineligible for surgical approaches. The StratX Platform is a cloud-based quantitative computerized tomography (CT) analysis service that provides physicians with an easy-to-read report that it has designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves.